Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (392)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (17)
Highly specialised technologies guidance (10)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (303)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 351 to 375 of 404
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Targeted Muscle Reinnervation for refractory pain after limb amputation
Interventional procedures guidance
20 June 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Technology appraisal guidance
11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Technology appraisal guidance
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Technology appraisal guidance
TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]
Technology appraisal guidance
16 July 2025
Teprotumumab for treating thyroid eye disease [ID6432]
Technology appraisal guidance
20 August 2025
Third molars (impacted) - prophylactic removal [ID898]
Technology appraisal guidance
TBC
Tirzepatide for managing overweight and obesity [ID6179]
Technology appraisal guidance
14 January 2025
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]
Technology appraisal guidance
TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
Technology appraisal guidance
TBC
Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessation
NICE guideline
4 February 2025
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
Highly specialised technology
TBC
Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment
Health technology evaluation
22 May 2025
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Technology appraisal guidance
TBC
Total hip arthroplasty using the superpath approach for osteoarthritis
Interventional procedures guidance
TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Technology appraisal guidance
TBC
Transcatheter aortic valve implantation for native aortic valve regurgitation
Interventional procedures guidance
11 June 2025
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment
Health technology evaluation
8 January 2025
Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia
Interventional procedures guidance
8 January 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Technology appraisal guidance
10 September 2025
Treatments for non-small-cell lung cancer [ID6234]
Technology appraisal guidance
TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891
Technology appraisal guidance
TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Technology appraisal guidance
TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Technology appraisal guidance
TBC
Previous page
1
…
13
14
Current page
15
16
17
Page
15
of
17
Next page
Results per page
10
25
50
All
Back to top